Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: allosteric modulators - Addex Therapeutics

Drug Profile

Research programme: allosteric modulators - Addex Therapeutics

Alternative Names: A2A PAM; ADX 68692; ADX-71743; ADX-71943; ADX-92639; Cpd 23; FSH NAM; FSHR/LHR NAM for sex hormone dependent tumours and reproductive system disorders - Addex Therapeutics; GABA-BR PAM for overactive bladder - Addex; GABABPAMs; IL1R1 NAM (CD121a); mGlu2 NAM; mGlu3 PAM; mGlu4 PAM; mGlu7 NAM; mGluR2 NAM; mGluR3 NAM; mGluR3 PAM; mGluR7 NAM; Orexin 2R NAM; TNFR1 NAM (CD120a); TNFR1 NAM (TNF receptor superfamily); TrkB PAM (RTK superfamily) - Addex Therapeutics; TrkB receptor agonists - Addex; TrkB receptor modulators - Addex; TrkBPAM

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Pharmaceuticals; Addex Therapeutics
  • Class Analgesics; Neuroprotectants; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Adenosine A2 receptor modulators; Chorionic gonadotropin modulators; Follicle stimulating hormone modulators; GABA B receptor agonists; Interleukin 2 receptor modulators; Luteinising hormone modulators; Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 7 modulators; Metabotropic glutamate receptor modulators; Orexin receptor type 2 modulators; Ovarian follicle modulators; TrkB receptor agonists; TrkB receptor modulators; Tumour necrosis factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Autistic disorder; Charcot-Marie-Tooth disease; Cognition disorders; Fragile X syndrome; Neurodegenerative disorders; Parkinson's disease; Polycystic ovary syndrome; Post-traumatic stress disorders; Substance-related disorders
  • No development reported Alzheimer's disease; Anxiety disorders; Endometriosis; Huntington's disease; Major depressive disorder; Pain; Urinary incontinence; Visceral pain
  • Discontinued Gastro-oesophageal reflux; Gout; Inflammatory bowel diseases; Osteoarthritis; Osteoporosis; Pregnancy; Prostate cancer; Psoriasis; Rheumatoid arthritis; Sleep disorders

Most Recent Events

  • 08 Oct 2019 Addex Therapeutics plans clinical development for Substance-related disorders (Addiction) by the end of 2020
  • 08 Oct 2019 Preclinical for Parkinson's disease in Switzerland (PO)
  • 08 Oct 2019 Preclinical trials in Cognition disorders in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top